KAUST startup Wayakit has partnered with Swissport International AG to provide its disinfecting products at Jeddah, Dammam, and Riyadh airports. Wayakit's antiviral formulation eliminates 99.999% of bacteria, viruses, and the SARS-CoV-2 strain in 30 seconds. Swissport will use Wayakit to disinfect aircraft and buses, helping to curb the spread of COVID-19 and restore passenger confidence. Why it matters: This partnership highlights the growth of the Saudi startup ecosystem and KAUST's role in fostering innovation and supporting local entrepreneurs in developing advanced biotechnological solutions for critical challenges.
An article from KAUST discusses the impact of COVID-19 on automation, material science, and VR. It suggests increased automation, voice activation, and motion detection to reduce transmission in public spaces. KAUST faculty member Derya Baran is working on antimicrobial materials for high-touch locations, and KAUST is exploring VR for virtual labs. Why it matters: The pandemic is accelerating the adoption of AI-driven solutions and advanced materials research within Saudi Arabia to address public health challenges.
KAUST researchers have discovered that combining ultraviolet sunlight with phages increases the susceptibility of antibiotic-resistant bacteria to sunlight disinfection. This breakthrough addresses the growing threat of antimicrobial resistance, as the rate of discovering new antibiotics has slowed. The team demonstrated this method's effectiveness against a pathogenic E. coli strain found in Saudi wastewater. Why it matters: This research offers a promising alternative to traditional antibiotics, particularly relevant in regions like Singapore and the GCC where treated wastewater is a crucial water supply source.
KAUST startup Wayakit has inaugurated its first production pilot plant in Saudi Arabia, with a capacity of up to 20,000 liters of cleaning and disinfection bio-formulations per day. The plant aims to satisfy national demand for cleaning and disinfection products. Wayakit's products tackle the transmission of communicable diseases, contributing to both the national economy and the health of citizens. Why it matters: This pilot plant supports Saudi Vision 2030's National Industrial Strategy by building a sustainable facility for environmentally friendly cleaning products.
KAUST's Water Desalination and Reuse Research Center (WDRC) is dedicated to reducing the energy footprint of desalination, with Saudi Arabia being the largest producer of desalinated water globally. Biofouling, caused by organisms like the bay barnacle, increases the energy required for desalination and affects various sectors, including medical devices and marine vessels. Researchers at WDRC, including Professor Matthew McCabe and Director Johannes Vrouwenvelder, are exploring novel desalination technologies and anti-fouling agents to combat biofouling. Why it matters: Addressing biofouling is crucial for reducing the economic and ecological costs of desalination in water-scarce regions like Saudi Arabia and improving efficiency across multiple industries.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.